Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CCL2 | P13500 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14392106 | 1.00 | PRCP (0.38) | PRCPBRD4CCL2NOTUMOPRM1 | |
| SCHEMBL15468333 | 0.74 | HTR2A (0.40) | PRCPBRD4CCL2NOTUMOPRM1 | |
| SCHEMBL15468334 | 0.71 | PRCP (0.38) | PRCPBRD4CCL2NOTUMOPRM1 | |
| SCHEMBL10586774 | 0.67 | — | — | |
| SCHEMBL10586778 | 0.67 | — | — | |
| SCHEMBL7713258 | 0.67 | ADRA2A (0.40) | PRCPOPRM1HTR2AHTR2CHTR2B | |
| SCHEMBL10079284 | 0.67 | OPRM1 (0.42) | PRCPOPRM1HTR2AHTR2CHTR2B | |
| SCHEMBL22861976 | 0.65 | BRD4 (0.45) | BRD4CCL2OPRM1HTR2AHTR2C | |
| SCHEMBL13419845 | 0.65 | DDB1 (0.39) | OPRM1HTR2AHTR2CHTR2B | |
| SCHEMBL14170111 | 0.64 | BRD4 (0.38) | PRCPBRD4NOTUMOPRM1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648094-B2 | IAP BIR domain binding compounds | PHARMASCIENCE, INC. (CA) | 2014-02-11 | — | — | US | disclosed |
| US-8648094-B2 | IAP BIR domain binding compounds | PHARMASCIENCE, INC. (CA) | 2014-02-11 | — | — | US | disclosed |
| US-20120195915-A1 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2012-08-02 | — | — | US | disclosed |
| US-20120195915-A1 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2012-08-02 | — | — | US | disclosed |
| US-8163792-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2012-04-24 | — | — | US | disclosed |
| US-8163792-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2012-04-24 | — | — | US | disclosed |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120195915-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | PRCP 2311/4885BRD4 635/4885CCL2 1096/4885 |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | PRCP 2311/4885BRD4 635/4885CCL2 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.